What question did this study set out to answer?

To explore a combined approach of alpha particle radiotherapy and CTLA-4 inhibition in overcoming radioresistance and immune evasion in KRAS mutant pancreatic cancer.

March 7, 2026Cancer Research

Abstract A009: Synergistically overcoming KRAS-driven radioresistance and immune evasion in PDAC with alpha particle radiotherapy and anti-CTLA-4

View Full Paper

Ask AI

Bookmark

Authors

MRMarco Reis PMPoliana Camila Marinello ARAlexandre Rubinstein

Discussion

Member takes

Overview

Demonstrates the synergy of alpha particle radiotherapy and CTLA-4 inhibition in pancreatic cancer, suggesting a new treatment strategy.

Key Points

To explore a combined approach of alpha particle radiotherapy and CTLA-4 inhibition in overcoming radioresistance and immune evasion in KRAS mutant pancreatic cancer.
Used mt KRAS murine PDAC model (KPC cell line) for treatment evaluations.
Administered Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) intratumorally.
Incorporated CTLA-4 inhibition through anti-CTLA-4 antibodies (aCTLA-4) administered every 3 days for targeted immunotherapy.
Monitored local tumor response and systemic immunity with different injection timings.
Evaluated tumor growth delay and regression rates among treatment groups.
Combined treatment showed a significant increase in tumor growth delay compared to controls and monotherapies (p<0.05).
70% of combined therapy mice survived beyond day 39, while monotherapies reached euthanasia criteria.
40% of combined treatment group achieved complete tumor regression by day 30 without regrowth upon rechallenge.
A significant synergistic effect between Alpha DaRT and aCTLA-4 was observed (p<0.0001).

Cite This Study

Reis et al. (2026) studied this question.

synapsesocial.com/papers/69abc1765af8044f7a4ea1e4 https://doi.org/10.1158/1538-7445.rasoncother26-a009

View Full Paper

Ask AI

Bookmark

March 7, 2026Cancer Research

Abstract A009: Synergistically overcoming KRAS-driven radioresistance and immune evasion in PDAC with alpha particle radiotherapy and anti-CTLA-4

View Full Paper

Ask AI

Bookmark

Authors

MRMarco Reis PMPoliana Camila Marinello ARAlexandre Rubinstein

Discussion

Member takes

Overview

Demonstrates the synergy of alpha particle radiotherapy and CTLA-4 inhibition in pancreatic cancer, suggesting a new treatment strategy.

Key Points

To explore a combined approach of alpha particle radiotherapy and CTLA-4 inhibition in overcoming radioresistance and immune evasion in KRAS mutant pancreatic cancer.
Used mt KRAS murine PDAC model (KPC cell line) for treatment evaluations.
Administered Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) intratumorally.
Incorporated CTLA-4 inhibition through anti-CTLA-4 antibodies (aCTLA-4) administered every 3 days for targeted immunotherapy.
Monitored local tumor response and systemic immunity with different injection timings.
Evaluated tumor growth delay and regression rates among treatment groups.
Combined treatment showed a significant increase in tumor growth delay compared to controls and monotherapies (p<0.05).
70% of combined therapy mice survived beyond day 39, while monotherapies reached euthanasia criteria.
40% of combined treatment group achieved complete tumor regression by day 30 without regrowth upon rechallenge.
A significant synergistic effect between Alpha DaRT and aCTLA-4 was observed (p<0.0001).

Cite This Study

Reis et al. (2026) studied this question.

synapsesocial.com/papers/69abc1765af8044f7a4ea1e4 https://doi.org/10.1158/1538-7445.rasoncother26-a009

View Full Paper

Ask AI

Bookmark